ArticleCureus2026
A Five-Year Institutional Experience With Spatially Fractionated Radiation Therapy for Palliative Management of Bulky Tumors Across Diverse Anatomical Sites.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Treating bulky tumors that are ineligible for surgery or resistant to chemotherapy is a significant and challenging problem. High-dose, high-precision radiation therapy is an alternative for these patients. Spatially fractionated radiation therapy (SFRT) utilizes a combination of high radiation doses targeted in an equidistant configuration and random distribution to the tumor and low-radiation doses with homogenic distribution to induce an immunological response against the tumor. The present series explores our five-year experience using SFRT as palliative treatment for bulky tumors from different anatomical locations. Methods From March 2019 to June 2024, we treated 21 patients with bulky tumors (>6 cm) in different anatomical locations with SFRT. Patients received doses of 18-24 Gy in high-dose regions and 5 Gy in low-dose regions. Tumoral response was evaluated through Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Additionally, toxicity, changes in quality of life, and overall survival were measured. Results After an average follow-up of 36 weeks, 52% (n=11) patients maintained a stable disease, 38% (n=8) had a partial response, 4.76% (n=1) had a complete response, and 4.76% (n=1) had disease progression. The average tumor size at the end of treatment was 12.89 cm (SD=9.48) compared to the initial size of 15.19 cm (SD=7.48) (T-test,p=0.014). Patients had a decrease in the Visual Analogue Scale (VAS) score from 6.2 (SD=3.0) before treatment to 1.1 after (SD=1.46) (T-test,p=
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.